Scope, Claim Coverage, and US Patent Landscape for US 7,659,282 (Dextromethorphan + Quinidine for Pseudobulbar Affect)
US 7,659,282 is a method-of-treatment patent centered on a tight dosing relationship between dextromethorphan (DM) and quinidine (Q), specifically for pseudobulbar affect (PBA) or emotional lability. Its claims are narrower than broad “DM/quinidine for PBA” compositions because the inventive constraint is the dextromethorphan-to-quinidine weight ratio (≤ 1:0.5) coupled to defined daily dose ranges (DM about 20–80 mg/day; quinidine 10 to <30 mg/day). That ratio constraint is likely to be the key infringement fulcrum against generics and “authorized generic” versions that use different quinidine dosing or different DM:Q ratios.
What is US 7,659,282’s core invention and what does it cover?
Featured snippet answer: US 7,659,282 claims methods of treating pseudobulbar affect/emotional lability using dextromethorphan in combination with quinidine where DM is ~20–80 mg/day and Q is 10 to <30 mg/day, with DM:Q weight ratio ≤ 1:0.5.
Claim 1 is the independent claim with the ratio and dosing “gate”
The independent claim requires all of the following:
- Indication: treating pseudobulbar affect or emotional lability.
- Drug combination: dextromethorphan administered with quinidine.
- Daily dose ranges:
- Dextromethorphan: about 20 mg/day to about 80 mg/day
- Quinidine: about 10 mg/day to less than about 30 mg/day
- Ratio proviso:
- weight-to-weight ratio of dextromethorphan to quinidine is 1:0.5 or less
Interpreted as DM/Q ≤ 2.0 (since 1:0.5 corresponds to DM:Q = 2:1); the proviso bars formulations where DM outweighs quinidine beyond that threshold.
This structure matters legally because a design-around can be achieved by moving outside the ratio, outside the quinidine daily dose band, or outside the DM daily dose band, even if DM+quinidine is still used for the same indication.
Claim 2 narrows the treated population (etiology limitation)
Claim 2 limits the method to when PBA/emotional lability is caused by:
- neurodegenerative disease/condition, or
- brain injury.
This kind of claim can be useful in enforcement where the accused use is for PBA due to ALS, MS, dementia syndromes, stroke/TBI, etc. If a product is used broadly for PBA without tying to those causes, claim 2 might be harder to map to real-world prescribing.
How do claims 3–6 expand or narrow the administration scheme?
What about single daily vs multiple daily doses?
- Claim 3: dextromethorphan and quinidine administered as one combined dose per day.
- Claim 4: dextromethorphan and quinidine administered as at least two combined doses per day.
- Claim 12: dextromethorphan and quinidine administered in separate doses.
Practically, these claims address multiple product/packaging and dosing regimens:
- a single daily fixed-dose combination,
- split dosing, and
- separate pills taken in coordinated dosing.
A generic or repackaged combination typically still uses fixed-dose schedules; claim 12 is relevant where accused conduct uses separate formulations (for example, two NDCs) that are taken on the same day for PBA.
Are the dependent dose ranges meaningful?
- Claim 5: quinidine about 20 mg/day to about 30 mg/day.
- Claim 6: dextromethorphan about 20 mg/day to about 60 mg/day.
These are incremental “fences” within the broader claim 1 bands. They matter for:
- partial overlap scenarios where DM falls inside claim 1 but quinidine falls outside claim 5, or vice versa;
- proving infringement if the accused label/dosing uses a specific DM and Q regimen.
What formulations and salts are protected by US 7,659,282?
Which salt forms are in-scope?
Claim 7: at least one of quinidine and dextromethorphan is in a pharmaceutically acceptable salt form.
Claim 8: salt types include:
- salts of free acids,
- inorganic salts,
- sulfate salts,
- hydrochloride salts,
- hydrobromide salts.
Claim 9 and 10 provide specific daily dosing examples tied to specific salt forms:
- Claim 9: about 20 mg quinidine sulfate per day.
- Claim 10: about 60 mg dextromethorphan hydrobromide per day.
Claim 11: about 60 mg dextromethorphan hydrobromide per day (without necessarily tying quinidine to sulfate in that dependent claim).
Coverage implication: A manufacturer can’t easily avoid claim 1 by changing the salt form if the active drugs remain within the claimed dose/range/ratio and the method is still practicing the claimed DM+Q dosing regimen.
How tight is the dosing ratio constraint and what are the design-around angles?
Ratio math that controls infringement risk
Claim 1 requires DM:Q ≤ 2:1. Examples:
- If quinidine is 10 mg/day, DM must be ≤ 20 mg/day (to satisfy DM/Q ≤ 2).
- If quinidine is 20 mg/day, DM must be ≤ 40 mg/day.
- If quinidine is 25 mg/day, DM must be ≤ 50 mg/day.
- If quinidine is 29 mg/day (less than 30), DM must be ≤ 58 mg/day.
This means the claim does not simply cover “typical DM+Q product” dosing unless that product’s DM/Q relationship stays under the threshold. If a competitor uses higher DM per day while holding quinidine at a lower daily dose, it can fall outside the ratio proviso even if the daily ranges for each drug overlap.
Three likely design-around levers
- Raise quinidine relative to DM (or reduce DM relative to quinidine) to stay under the ratio, or exceed the ratio to avoid infringement.
- Move quinidine outside 10–<30 mg/day, or DM outside 20–80 mg/day.
- Change the clinical regimen such that the daily administration does not meet the claim 1 ranges and ratio.
From an R&D strategy standpoint, the ratio proviso is the most litigation-relevant because it creates a single composite constraint rather than only independent drug dose windows.
What does the patent landscape likely look like around US 7,659,282 for PBA?
A complete “US landscape” requires checking the full patent family, prosecution history, and the Orange Book for the exact reference listed drug (RLD) associated with the DM+quinidine regimen. You provided only the claim text and the patent number, not the RLD or application link. Without those identifiers, a reliable mapping to competing patents and Orange Book listings cannot be done without risking incorrect assertions.
Accordingly, this analysis is confined to claim-scope mechanics and the immediate legal coverage perimeter implied by the claim set you supplied.
How strong are the claims for enforcement against generics or rebranded DM+quinidine?
What makes the claims enforceable
- The claim is method-based but tightly tied to a combination and explicit daily dosing and ratio. That can support straightforward mapping to a prescribed regimen if the regimen matches the claim parameters.
- Dependent claims cover multiple dosing schedules (single daily, split doses, separate dosing), reducing easy procedural avoidance.
What weakens enforcement
- If an accused regimen uses a DM/Q ratio above the ≤ 1:0.5 threshold, claim 1 can fail even if DM and Q individually fall within their independent ranges.
- Claim 2 adds an etiology limitation for a subset population. Unless prescribing and practice patterns can be tied to neurodegenerative disease/brain injury causes of PBA, claim 2 may not be provable.
- Method claims are harder to enforce when real-world use deviates from the regimen, or where the accused product label instructs dosing outside the claim constraints.
Litigation and settlement impact: what claim scope implies about potential disputes?
Without case captions, docket numbers, or settlement terms, litigation analysis cannot be completed accurately. Claim scope does, however, suggest the usual dispute pattern:
- Accused parties tend to argue the DM/Q ratio or daily dosing does not meet the proviso.
- Plaintiffs tend to rely on the dosing schedule actually used (label, physician instructions, and any controlled trials) and on salt-form mapping to show equivalence of administration.
Key takeaways
- US 7,659,282 is built around a method for PBA/emotional lability requiring a specific DM+quinidine relationship, anchored by:
- DM about 20–80 mg/day,
- quinidine about 10–<30 mg/day, and
- DM:Q weight ratio ≤ 1:0.5 (DM/Q ≤ 2).
- Dependent claims broaden the method to various administration patterns (single vs split dosing; combined vs separate dosing) while adding narrower dose bands and salt-form provisions.
- The ratio proviso is the highest-leverage constraint for infringement and design-around work. Shifting quinidine dose up/down relative to DM can determine whether the method lands inside or outside claim 1.
- Etiology (neurodegenerative disease/brain injury) limits claim 2 and can constrain enforcement where PBA causes are not matched.
FAQs
1) What is the single most important parameter to evaluate for infringement of US 7,659,282?
The DM:quinidine weight ratio proviso in claim 1 (≤ 1:0.5), coupled to the daily dose bands.
2) Does changing the salt form avoid US 7,659,282?
Not if the claimed DM and quinidine salt forms still deliver the claimed daily amounts and the method remains within the ratio and dosing constraints.
3) Can a product avoid infringement by using separate pills for DM and quinidine?
Claim 12 expressly covers separate doses, so separation alone is not a workaround if the overall method meets the claim 1 parameters.
4) Which dependent claims are most relevant for specific dosing regimens (e.g., quinidine ~20–30 mg/day)?
Claims 5 (quinidine about 20–30 mg/day) and 6 (DM about 20–60 mg/day), plus claims 9–11 for specific sulfate/hydrobromide daily examples.
5) Does claim 2 broaden or narrow the method compared with claim 1?
It narrows by limiting to PBA/emotional lability caused by neurodegenerative disease/condition or brain injury.
References
- US Patent 7,659,282. (claims provided in prompt).
